Block of Risk Stratification

1 In your opinion, are there clear recommendations on risk stratification? /
2 In your opinion, is age determinant for risk stratification? /
3 In your opinion, is thrombosis history determinant for risk stratification? /
4 In your opinion, should platelet count at diagnosis be included in risk assessment? /
5 In your opinion, does a clear relationship exist between platelet count and thrombotic event occurrence? /
6 In your opinion, is a platelet count ≥ 1.500 x 109/L a variablepredicitve of hemorrhagic risk? /
7 In your opinion, should hypertension assessment be considered regarding treatment election in ET patients? /
8 In your opinion, should diabetes assessment be considered regarding treatment election in ET patients? /
9 In your opinion, should hypercholesterolemia assessment be considered regarding treatment election in ET patients? /
10 In your opinion, should smoking habit assessment be considered regarding treatment election in ET patients? /
11 In your opinion, should obesity assessment be considered regarding treatment election in ET patients? /
12 Do you consider necessary the screening of thrombophilia at the time of ET diagnosis? /
13 In your opinion, is the IPSET-thrombosis system useful for thrombotic risk assessment? /
14 In your opinion, is the IPSET-survival system useful for survival assessment? /
15 Do you consider adequate the conventional high/low risk assessment classification? /
16 Do you consider convenient the inclusion of an intermediate-risk group in the conventional risk assessment classification? /
17 Regarding thrombosis risk assessment, do you consider important to take the presence of leukocytosis into account? /
18 Regarding thrombosis risk assessment, do you consider important to take the JAK2V617F mutational status into account? /
19 Do you consider important to monitor JAK2V617F allelic burden during clinical follow-up? /
20 In your opinion, could CALR mutational status provide prognosis information? /
21 Do you consider necessary to re-classify risk assessment when any cardiovascular risk factor appears? /